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In an earlier study in 2002 [1] we showed that
of 101 persons applying for a disability pension
for psychiatric reasons, a psychiatric diagnosis
that affected their ability to work, could only be
confirmed in 83%. Furthermore, and even more
importantly, only 64% of these cases were receiv-
ing any psychiatric treatment and only 20% ade-
quate drug therapy. 
Since this time there has been a great deal of
discussion on the increasing numbers of people
receiving a disability allowance in Switzerland.
Questions under study: We evaluated whether,
compared to the 2002 situation, application be-
haviour, expressed in more accurate diagnoses
and treatment plans before filing the application
for disability pension, has changed.
Methods: We examined 124 of 132 subjects who
were assessed for the Swiss Invalidity Insurance at
the psychiatric outpatient department of the Uni-
versity Hospital, Basel in 2004. Eight persons did
not agree to participate in the study. The results
were compared with the results of our earlier study. 
Results: There were some significant differ-
ences between the 2002 and 2004 applicants. In
2004, there was a tendency to an even lower pro-
portion of subjects with a psychiatric diagnosis af-
fecting their ability to work (73% vs 83%, p <.1).
Of these applicants, significantly more than in the
previous study reported taking specific psychiatric
medication (74% vs 50%, p <.01). 
However, the proportion of patients, who
were sufficiently medicated as documented by ad-
equate drug serum levels (37%) or who were re-
ceiving any form of psychotherapy in a broad
sense (30%), was still fairly low.
Furthermore, there was a lower proportion of
affective disorders as the primary diagnosis (49%
vs 62%, p <.1).
Conclusions: The findings from our earlier
study, namely, that psychiatric applicants for a dis-
ability pension were not sufficiently diagnosed
and treated before the application, could largely
be replicated. Only minor changes could be ob-
served over the last couple of years, with psy-
chotropic medications being taken by more appli-
cants, which might partly be due to the ongoing
discussion.
Key words: Swiss invalidity insurance; disability
insurance; disability pension; psychiatric expertise;
compliance; drug monitoring; delay of diagnosis and
treatment
Summary 
The Federal Invalidity Insurance (IV) is one
arm of the social insurance network of Switzerland.
Invalidity insurance contribution is mandatory. An
insured person may apply for diverse benefits. The
main benefits provided by the IV system are in the
form of rehabilitation measures, aimed at promot-
ing the professional (re)integration of disabled in-
dividuals and thus improving/restoring their earn-
ing capacity. The guiding principle is “rehabilita-
tion before pension”. Rehabilitation measures are
medical measures, supply of appliances, occupa-
tional measures and daily cash benefits as ancillary
benefits. A person is only entitled to an invalidity
pension if the rehabilitation option has been ex-
hausted. The degree of disability (at least 40%) de-
termines the type of pension [2].
The total number of people claiming an IV-
pension has increased steadily in recent years, both
in terms of the overall number of pensions awarded
and pensions awarded specifically for mental health
reasons. In both groups the number of new pen-
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as the number of new pensions granted still ex-
ceeded the number of pensions discontinued, the
overall number has continued to climb [3].
A similar trend has been observed in other
countries, such as Belgium, Canada, Germany, The
Netherlands and Sweden [4]. For example, in Fin-
land the number of disability pensions granted due
to depression tripled between 1987 and 1994, de-
spite improved drug therapies and other means of
treatment [5]. The reasons given for this include
the economic recession, changes in the diagnostic
system, improved diagnostic skills or a significant
deterioration in the functional ability to cope with
stress [4, 5]. 
In Switzerland in 1985, 24% of newly issued
pensions were granted for mental illness [6]. In
2004 and 2005 this figure climbed to 40% [7]. Var-
ious factors were cited as possible reasons for this
increase. These include the mounting psychologi-
cal stress to which people are exposed in their work-
place and at home with a related increase in men-
tal illness, more liberal approaches to assessing
mental illness and granting pensions, an increasing
tendency to grant disability pensions to alleviate
social problems such as unemployment, an in-
creasing belief among insured persons that after
having paid insurance contributions for a number
of years they are fundamentally entitled to a pen-
sion, the higher proportion of immigrants and their
attendant psychosocial problems such as difficul-
ties in adjusting to a new culture and, finally, the
process of determining the pension entitlement it-
self, which can drag on for several years and itself
be a cause of emotional/psychological distress [8–
10]. Little attention has so far been paid to exam-
ining the role played by the pension applicants and
their treating physicians.
In 2002 we had therefore conducted a study on
all 101 applicants for a pension for psychiatric rea-
sons, who were referred to our psychiatric depart-
ment for a psychiatric expertise by the Swiss Inva-
lidity Insurance. This study revealed that  a psychi-
atric diagnosis could be confirmed in only 83% of
the applicants. At the time of the expertise only
64% of the applicants were in regular psychiatric
treatment and only 20% were receiving adequate
drug therapy [1]. 
Since this time there has been considerable dis-
cussion in both the Swiss public and between health
professionals and psychiatrists on the practice of
granting disability pensions.
In the current study we therefore tried to repli-
cate the results of the 2002 study, with special em-
phasis on the question of whether application be-
haviour had changed since then. We hypothesized
that as a result of the ongoing discussion, assess-
ment of diagnosis and of the ability to work would
have improved and that treatment would have been





















1997 1998 1999 2000 2001 2002 2003 2004 2005 2006year
mental disorders – new disability pensions
all causes – new disability pensions
mental disorders – total disability pensions


































and due to all causes,
1997–2005 [3].
Patients and methods
Every year the cantonal office of the Swiss Invalidity
Insurance in Basel refers a certain number of applicants,
especially immigrants and women, to our psychiatric out-
patient department for a psychiatric expertise regarding
the question of disability pension. The referral pattern
has not changed over the years. 
In the current study we included 124 of 132 subjects
referred in 2004. Eight persons declined participation in
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the study. Five of these were concerned that their data
could be misused and three did not want to “support the
Invalidity Insurance”. 32 subjects (26%) were already in
receipt of a partial or full disability pension. All applicants
were examined thoroughly by at least two psychiatrists,
of whom at least one was fully qualified. The psychiatrists
had six, respectively, eight years of experience.
Psychopathological symptoms were routinely moni-
tored using the AMDP-Scale (Arbeitsgemeinschaft für
Methodik und Dokumentation in der Psychiatrie) [11], a
well validated instrument commonly used in German
speaking countries. Psychiatric diagnoses were estab-
lished according to the International Classification of
Diseases (ICD-10) [12].
All subjects also completed a questionnaire measur-
ing their physical and mental symptoms (SCL-90-R)
[13]. In cases where further information was needed in
order to confirm diagnosis or to assess the subject’s ca-
pacity to work, further questionnaires and/or psychologi-
cal testing were conducted. 
The data on medical history, previous treatment, di-
agnosis and appraisal of capacity to work were obtained
in a psychiatric interview and were recorded in a stan-
dardized form. These data were checked against the indi-
vidual psychiatric-medical file and gaps in information
were filled accordingly. Copies of missing medical re-
ports were obtained from the institutions in question
after obtaining patient consent. 
If the subjects reported that they were currently on
psychiatric medication, blood serum levels were routinely
checked with his or her consent. If somatic conditions
that could conceivably influence the psychiatric diagnosis
were present, a somatic expertise was ordered. Upon con-
clusion of the examination and after obtaining disclosure
permission, the assessee and the treating physician and/or
psychotherapist were verbally informed of the results of
the expertise and our treatment recommendations. 
In the case of non-German-speaking subjects, a na-
tive-speaking interpreter was present, unless the subject
expressly refused. This procedure is consistent with the
relevant guidelines for assessing mental disorders [14].
For ethical reasons we ensured that participation or
non-participation in the study could not influence the
recommendations of the experts. To this end the consent
forms were managed by a neutral third person and the
patient’s decision whether or not to participate in the
study was not communicated until after the expertise had
been completed. 
The data were collected so as to preserve anonymity.
They were evaluated using version 11.0 of the SPSS sta-
tistics program. To compare proportions we used the
Chi-Square test. As level of significance we took 0.1.
Concerning the limitation of the study one should
consider that the two year interval between the first study
2002 and the second study 2004 is rather short.
The study was approved by the Research Ethics
Committee of the Cantons of Basel-Stadt and Basel-
Land. Written informed consent was obtained from each
of the 124 study participants.
Results
Results of the current 2004 study
Of the 124 subjects examined, 63 were women
(51%) and 61 men (49%). Their ages ranged from
20 to 62 years, the average being 43.7 years (me-
dian = 44 years). 
Subjects whose mother tongue was a language
spoken in former Yugoslavia were most numerous
(37 = 30%), followed by German (35 = 28%),
Turkish (27 = 22%) and Italian (10 = 8%). The re-
maining subjects originated from Spain (4),
France (3), Algeria, Finland, India, Israel, Liberia,
Portugal, Sri Lanka and Vietnam (1 each).
In 34 of the 124 subjects (27%) no psychiatric
diagnosis, which might be expected to impair
their capacity to work, could be made.
In the remaining 90 cases, a total of 104 psy-
chiatric diagnoses were made, the largest propor-
tion of these were affective disorders (49%), fol-
lowed by neurotic and somatoform disorders
(25%). Table 1 shows the percentage of applicants
with the respective diagnosis.
Of the 90 subjects with a current psychiatric
diagnosis, 67 (74%) reported that they regularly
took specific psychiatric medication (antidepres-
sants, neuroleptics or mood stabilizers). In 53 of
these cases, blood serum levels were measured
(the remaining subjects did not agree to submit to
a blood test). The serum levels of the drugs in
question were within the therapeutic range in 26
(49%) of the subjects tested, but were significantly
below the therapeutic range in 20 (38%) of the
subjects. In 7 (13%) cases, no traces of the drug in
question were detected. This means that only
37% of the 90 subjects could be demonstrated to
be taking psychiatric drugs in sufficiently high
doses. 
71 (79%) of the 90 subjects with a psychiatric
diagnosis reported that they were currently un-
dergoing “some sort of psychiatric-psychothera-
peutic treatment”. This included, for example,
short sessions with a general practitioner and in-
cluded prescription of medication. 39 (43%) re-
ported being in current “psychotherapy”. How-
ever, only 27 (30%) fulfilled the minimal criterion
of having had at least one psychotherapy session
per month for at least six months. 26 (29%) of the
subjects reported having been hospitalized in a
psychiatric clinic because of the actual disorder.
Capacity to work judged from a psychiatric
perspective by our experts is summarised in table 2.
From this the experts derived the attendant re -
commendation concerning disability pension 
entitlement. Pensions were subsequently granted
or denied by the disability insurance office on the
basis of these recommendations together with
their own experience. In 20 (22%) of the cases
with a psychiatric diagnosis, the condition was not
considered serious enough to warrant recom-
mending a pension. In 17 (19%) of the cases, a full
disability pension was recommended.
Of the 124 subjects who applied for disability
insurance benefits, eight requested rehabilitation
measures, three job placement and 113 a disability
pension.
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The age structure of the group of subjects in
this study (2004: average age = 43.7 years, range
20–62 years) was very similar to that of the sub-
jects examined in the earlier study [1] (2002: aver-
age age = 43.3 years, range 21–65 years, p = n.s.).
For other comparisons between the two groups,
see Tables 3 a and 3 b.
There were some statistically significant dif-
ferences between the 2002 and 2004 groups. In
2004 there was a lower proportion of subjects
with a psychiatric diagnosis affecting the ability to
work (73% vs 83%, p <.1), a lower proportion of
affective disorders as primary diagnosis (49% vs
62%, p <.1), and highly significantly more pa-
tients reporting taking specific psychiatric med-
ication (74% vs 50%, p <.01). 
Diagnosis 2002 study (n = 101) 2004 study (n = 124)
n (%)1 n (%)1
F 0x (Organic mental disorders) 1 (1) 3 (2)
F 1x (Mental and behavioural disorders due to 7 (7) 3 (2)
psychoactive substance use) 
F 2x (Schizophrenia, schizotypal and delusional disorders) 3 (3) 10 (8)
F 3x (Mood disorders) 65 (64) 51 (41)
F 4x (Neurotic, stress-related and somatoform disorders) 22 (22) 26 (21)
F 6x (Disorders of adult personality and behaviour) 7 (7) 8 (6)
F 7x (Mental retardation) 0 (0) 2 (2)
F 9x (Behavioural and emotional disorders with onset  0 (0) 1 (1)
in childhood and adolescence)
No psychiatric diagnosis affecting capacity to work 17 (17) 34 (27)
1 % of applicants, multiple diagnoses possible 
Assessed capacity Number of subjects Disability pension 
to work recommendation of expert
n (%) n (%)
2002 / 2004 2002 / 2004 2002 / 2004 2002 / 2004
90% 0 / 4 (0) / (4) No pension: 34 / 20          (40) / (22)
80% 12 / 6 (14) / (7)
75% 5 / 5 (6) / (6)
70% 17 / 5 (20) / (6)
60% 19 / 16 (23) / (18) ¼ disability pension: 19 / 16 (23) / (18)
50% 19 / 25 (23) / (28) ½ disability pension: 19 / 25 (23) / (28)
40% 9 / 12 (11) (13) ¾ disability pension: 9 / 12 (11) / (13)
30% 3 / 7 (3) / (8) Full disability pension: 3 / 17 (3) / (19)
25% 0 / 2 (0) / (2)
20% 0 / 3 (0) / (3)
10% 0 / 1 (0) / (1)
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Discussion
This study shows, firstly, that there is still a
high proportion (more than a quarter) of appli-
cants for disability pension for mental reasons
who do not fulfil the diagnostic criteria for a psy-
chiatric disorder impairing their working capacity.
As there is a risk of medicalizing social problems,
for example, unemployment, social stress and fi-
nancial problems, the general practitioners or psy-
chiatrists of patients, who consider applying for a
pension for psychiatric reasons, should be aware
of this and decide if this patient really fulfils the
criteria of a mental disorder. In future a new pro-
cedure, developed by the Swiss Invalidity Insur-
ance allowing a voluntary early registration of
subjects certified unfit for work for more than
four weeks, may be helpful in reducing this risk.
Comparison of the 2004 results with the results of the 2002 study
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The target of this registration is early examina-
tion, diagnosis, treatment and rehabilitation [15].
Social problems are incorporated into the differ-
ential diagnosis. In 2004 even fewer subjects than
in 2002 could be diagnosed with a psychiatric
condition, according to ICD-10. However, among
those diagnosed, the conditions were more debili-
tating. Hence, over the period 2002–2004, in our
assessees a tendency was observed that, if someone
did in fact receive a psychiatric diagnosis, he was
more likely to be suffering from a more serious
psychiatric condition and receive better treat-
ment. Several reasons for this can be put forward,
such as the increased awareness concerning
 psychiatric disorders and treatment, a change in
behaviour, the change in referral behaviour of 
the Swiss Invalidity Insurance/cantonal office of
Basel, or even coincidence, considering the small
number of subjects included in the current study. 
Secondly, amongst those with a psychiatric
disorder the proportion of subjects who receive
psychiatric-psychotherapeutic help in the broad-
est sense of the term (30%), i.e. at least one psy-
chotherapy session per month, including general
practitioners as potential providers, and of those
who were sufficiently medicated (37%) are still
fairly low. “Psychotherapy” in the strict sense with
a higher frequency of sessions (once per week)
was not mentioned by any of the patients.
In both studies most of the psychiatric diag-
noses were in the group of affective or somato-
form disorders, which can be effectively treated
with medication and psychotherapy [16–19]. This
however, does not seem to be realised or accepted
by all physicians and their patients. Thus, educa-
tion of general practitioners and also other col-
leagues on special therapies may help them to im-
prove their motivation to refer such patients to
psychiatrists for specific psychotherapy and med-
ication. Especially in patients with somatoform
disorders, short-term interventions focussing on
the perception of feelings and a psychosomatic
understanding of illness may influence the moti-
vation for psychotherapeutic treatment positively
[20]. Compliance with medication can be influ-
enced by a good doctor-patient relationship, by
choosing a medication with high efficacy and lack
of side effects and by sufficient information on
mechanisms of action [21].
In the 2004 study as compared to the 2002
study, treatment numbers were considerably
higher with respect to reported current psychi-
atric-psychotherapeutic treatment in the broadest
sense of the term, use of psychiatric drugs, suffi-
cient dosage of psychiatric drug treatment and
psychiatric hospitalisation (table 3). Reasons for
this difference might be that in the 2004 study,
26% of the subjects were already receiving a par-
tial or full disability pension, in contrast to 11%
in the 2002 study. In several cases, when the pen-
sion had been granted some time previously, the
cantonal office may have imposed an obligation
Criterion 2002 study 2004 study absolute p-value#
(n = 101) (n = 124) difference
(90% CI)
n (%) n (%)
Subjects with a psychiatric diagnosis affecting their 84 (83) 90 (73) –10 (–19.0 to –1.0) 0.06
ability to work (capacity to work <100%) 
Subjects with psychiatric diagnosis resulting in disability 50 (50) 70 (56) 6 (–5.0 to 17.0) 0.30
(capacity to work ≤60%)
# Chi-Square test, level of significance 0.1
Criterion 2002 study 2004 study absolute p-value#
(n = 84) (n = 90) difference
(90% CI)
n (%) n (%)
Number of psychiatric diagnoses 105 104
Affective disorder as primary diagnosis 65 (62) 51 (49) –13 (–24.2 to –1.8) 0.06
Somatoform disorder as primary diagnosis 22 (21) 26 (25) 4 (–5.5 to 13.5) 0.49
Use of specific psychiatric medication reported 42 (50) 67 (74) 24 (12.3 to 35.7) <0.01
Blood serum concentration of psychiatric medication  16 (40) 26 (49) 9 (–8.0 to 26.0) 0.39
in the therapeutic range of n = 40 of n = 53
tested tested
Any psychiatric-psychotherapeutic treatment 71 (79)
Current “psychotherapy” reported 29 (35) 39 (43) 8 (–4.1 to 20.1) 0.24
Psychotherapy in the broadest sense 27 (30)
(at least one session per month)
# Chi-Square test, level of significance 0.1
Table 3 a





Results of the exper-
tises – comparison
between 2002 and
2004: subjects with a
psychiatric diagnosis
generally affecting
their ability to work
(capacity to work
<100%).
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for a consequent therapy, which the invalidity
pensioner had to prove after a specific time. In ad-
dition, knowledge of treatment options has grown
among both patients and doctors and public dis-
cussion in recent years has heightened awareness
of the need for treatment, which may also have
played a role. An important finding, however, is
that there is still a high proportion of patients
without sufficient psychiatric treatment. Similar
findings were reported by a Swiss study [22] on
131 severely depressed outpatients with algo-
rithm-guided antidepressant treatment. In this
study the dropout rate was 66%, the prevalence of
non-compliance, as documented from measured
plasma levels, was 23%. 
It is an internationally recognized phenome-
non that treatment of persons who apply for ben-
efits for psychiatric reasons, tends to be insuffi-
cient. In a Norwegian study involving 150 people,
who had applied for a disability or war pension on
psychiatric grounds, none of the applicants had
received prior psychiatric treatment [23]. A Polish
study involving 109 subjects, who had requested a
disability pension for psychiatric reasons, showed
that 28% of these people had had no contact
whatsoever with a psychiatrist and only 18% had
previously been in a psychiatric clinic [24]. A
Finnish study examined 277 subjects who had
been granted a disability pension due to depres-
sion. Only two thirds of these people had been
prescribed medication in an adequate dosage.
How many actually took the medication is not
known. Only 9% had psychotherapy on a weekly
basis [25]. A German study of 30 subjects diag-
nosed with depression or chronic pain and for
whom psychiatric expertises were prepared,
showed that blood serum levels of medication
were in the therapeutic range in only 30% of the
cases and in the vast majority no traces of the drug
were detected [26]. A meta-analysis on interna-
tional research on the prevalence of treatment for
depression in the general population revealed a
similar trend, independent of requested psychi-
atric expertises. Of the cases diagnosed with de-
pression, only about one quarter were provided
with adequate drug treatment [27].
Even though 74% of our 2004 subjects re-
ported taking specific medication, this could be
confirmed in only 37%. We reason that this might
be explained by malcompliance [26] or the fact
that the patients knew that a specific medication
could be important, which led them to falsely re-
port consumption during the expertise. Other
possibilities are the prescription of insufficient
doses by treating physicians [26]. In individual
cases a plasma level below the so-called therapeu-
tic range might have shown a sufficient clinical
improvement, as the “therapeutic range” is only a
statistical device describing the daily dosage range
within which the plasma levels of most patients
lie. A clear relationship between plasma concen-
tration and clinical effect has not been established
[28, 29]. Finally, some subjects may be fast metab-
olizers and thus might have blood levels below
the therapeutic range. If this is not tested for, they
might be wrongly suspected of lack of compli-
ance.
In conclusion, we are far from early diagnosis
and treatment. If we want to avoid a further in-
crease of disability pensions with all its negative
consequences for society and especially the indi-
viduals themselves, physicians should urgently re-
view their referral practice and refer patients with
mental problems and/or unexplained somatic
complaints to the psychiatrist much more often
and much earlier. Regarding the subjects claiming
a disability pension without a confirmed psychi-
atric diagnosis impairing their working capacity,
physicians and psychiatrists should become aware
of the risk of medicalizing social problems and
avoid raising false expectations in their patients.
In order to promote mental health and improve
working capacity, mental health diagnoses should
only be made in subjects actually suffering from
such disorders and adequate treatment must be
offered to those so diagnosed as early as possible.
We thank Mr Paul Meier, head of the Cantonal In-
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